This is the third indication for Vabysmo®, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema 1 Authorization is based on two phase III studies demonstrating early… Read More
We are thrilled to share that Nicole Desloges, our Senior Vice President of People, has been selected as an Excellence Awardee in the annual Canadian HR Awards! This recognition is… Read More
The Stem Cell Network (SCN) is pleased to announce the first of two national research funding competitions planned for SCN’s 2025-2029 funding cycle. This new competition will support world-class, translational,… Read More
TORONTO, ON – The National Advisory Committee on Immunization’s (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent among the preferential influenza vaccines, over standard dose… Read More
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and… Read More
